- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04110535
Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
September 27, 2019 updated by: Paion UK Ltd.
A Double-blind, Randomized Crossover Study to Assess the Subjective Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
A double-blind, randomized crossover study to assess the subjective abuse potential of intravenous remimazolam compared to midazolam and placebo in recreational CNS depressant users
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
83
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- PRA Health Sciences Early Development Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have provided written informed consent prior to the initiation of any protocolspecific procedures.
- Male and female adults, between 18 and 55 years of age, inclusive.
- Body mass index (BMI) within 19.0 to 33.0 kg/m2, inclusive (minimum weight of at least 50.0 kg at Screening).
- Healthy, as determined by having no clinically significant medical history, physical examination, 12-lead ECG, vital signs, or laboratory (including hematology, clinical chemistry, urinalysis, and serology) findings, as judged by the investigator.
Recreational CNS depressant user, defined as follows:
- ≥ 10 lifetime non-therapeutic experiences (ie, for psychoactive effects) with CNS depressants (eg, benzodiazepines, barbiturates, opioids, zolpidem, zopiclone, propofol/fospropofol, gamma-hydroxybutyrate)
- ≥ 1 non-therapeutic use of a CNS depressant within the 8 weeks prior to Screening
- ≥ 1 non-therapeutic use of benzodiazepines within the 12 months prior to Screening
- Must pass Qualification Phase (Drug Discrimination and Tolerability) eligibility criteria (Section 9.3.1 and 9.3.2, respectively).
- Female subjects must be of non-childbearing potential (postmenopausal, with > 1 year since last menses and a follicular stimulating hormone (FSH) value > 40 mIU/mL, or surgically or congenitally sterile), or, if of childbearing potential, must be using and willing to continue using highly effective contraception, defined as methods of birth control that result in a low failure rate (ie, less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or a vasectomized partner, for at least 1 month prior to Screening (at least 3 months for oral and transdermal contraceptives) and for at least 14 days after last study drug administration.
- Able to speak, read, and understand English sufficiently to allow completion of all study assessments.
- Must be willing to comply with the requirements and restrictions of the study.
Exclusion Criteria:
- Drug or alcohol dependence within the 12 months prior to Screening (except nicotine), as defined by the Diagnostic and Statistical Man ual of Mental Disorders, fourth edition, text revision (DSM-IV-TR), or any self-reported dependence or "addiction" within the subject's lifetime (except nicotine or caffeine).
- Subjects who have ever been in treatment for substance use disorder(s) (except smoking cessation).
- History or presence of any clinically significant cardiac, psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or other major disease at Screening, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results, including subjects with chronic renal failure or congestive heart failure.
- In the opinion of the investigator, the subject was at risk for respiratory depression, including subjects with obstructive apnea, upper airway obstruction, chronic obstructive pulmonary disease, acute or severe bronchial asthma, hypercarbia, or other severe cardio-respiratory disease.
- Positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- History of, or evidence at the time for, suicidal ideation with intent, with or without a plan or method, in the past 5 years or suicidal behavior in their lifetime or those who were actively suicidal based on the Columbia-Suicide Severity Rating Scale (C-SSRS).
- Unexplained significant and recent loss of consciousness, or history of significant head trauma with loss of consciousness.
- Reported history of acute narrow-angle glaucoma.
- Required concomitant treatment with any prescription or non-prescription medications (with the exception of hormonal contraceptives, hormone replacement, and acetaminophen) or natural health products (herbal remedies), including strong cytochrome P450 (CYP) 3A4 inhibitors or respiratory depressants, or could not safely discontinue these medications within 7 days or 5 half -lives (whichever is longer) prior to receiving study drug in the Qualification Phase and for the Duration of the study.
- Subject was using an investigational drug or device or had used such within the 30 days (or 5 half-lives, whichever is longer) prior to first drug administration in the Qualification Phase.
- Female subjects who were pregnant or lactating or who were planning to become pregnant within 14 days of last study drug administration.
- Subject had a prior history of any significant adverse reactions (including rash) to benzodiazepines and/or flumazenil, or known allergies to midazolam and/or flumazenil, or formulation components.
- Subject had unsuitable or difficult venous access or was unwilling or unable to undergo catheter insertion.
- Subject was an employee of the sponsor or research site personnel directly affiliated with this study or their immediate family member defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- A subject who, in the opinion of the investigator, was considered unsuitable or unlikely to comply with the study protocol for any reason (in each case, the investigator had to specify the reason).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
Saline injection
|
IV administration over 1 minute
|
EXPERIMENTAL: Remimazolam 5 mg
IV administration of remimazolam 5 mg
|
IV administration over 1 minute
Other Names:
|
EXPERIMENTAL: Remimazolam 10 mg
IV administration of remimazolam 10 mg
|
IV administration over 1 minute
Other Names:
|
ACTIVE_COMPARATOR: Midazolam 2.5 mg
IV administration of midazolam 2.5 mg
|
IV administration over 1 minute
|
ACTIVE_COMPARATOR: Midazolam 5 mg
IV administration of midazolam 5 mg
|
IV administration over 1 minute
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Liking VAS maximum effect (Emax)
Time Frame: 2 to 480 minutes postdose
|
Maximum effect (Emax) on the bipolar Drug Liking visual analogue scale (VAS)
|
2 to 480 minutes postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Liking VAS Minimum effect [Emin]
Time Frame: 2 to 480 minutes postdose
|
Minimum effect (Emin) on the bipolar Drug Liking visual analogue scale (VAS)
|
2 to 480 minutes postdose
|
Overall Drug Liking VAS (Emax/Emin)
Time Frame: 240 to 480 minutes postdose
|
Emax/Emin on the bipolar Drug Liking visual analogue scale (VAS)
|
240 to 480 minutes postdose
|
Take Drug Again VAS (Emax)
Time Frame: 240 to 480 minutes postdose
|
Maximum effect (Emax) on the unipolarTake Drug Again visual analogue scale (VAS)
|
240 to 480 minutes postdose
|
Good Effects VAS (Emax and TA_AUE)
Time Frame: 2 to 480 minutes postdose
|
Maximum effect (Emax) and TA_AUE on the unipolar Good Effects visual analogue scale (VAS)
|
2 to 480 minutes postdose
|
Bad Effects VAS (Emax and TA_AUE)
Time Frame: 2 to 480 minutes postdose
|
Maximum effect (Emax) and TA_AUE on the unipolar Bad Effects visual analogue scale (VAS)
|
2 to 480 minutes postdose
|
Alertness/Drowsiness VAS (Emin and TA_AUE)
Time Frame: Predose to 480 minutes postdose
|
Minimum effect (Emin) and TA_AUE on the bipolar Alertness/Drowsiness visual analogue scale (VAS)
|
Predose to 480 minutes postdose
|
Agitation/Relaxation VAS (Emin and TA_AUE)
Time Frame: Predose to 480 minutes postdose
|
Minimum effect (Emin) and TA_AUE on the bipolar Agitation/Relaxation visual analogue scale (VAS)
|
Predose to 480 minutes postdose
|
Any Effects VAS (Emax and TA_AUE)
Time Frame: 2 to 480 minutes postdose
|
Maximum effect (Emax) and TA_AUE on the unipolar Any Effects visual analogue scale (VAS)
|
2 to 480 minutes postdose
|
Paired Associates Learning (PAL) total error score (Emax and TA_AUE)
Time Frame: Predose to 480 minutes postdose
|
PAL test was conducted using the software CANTAB (Cambridge Cognition)
|
Predose to 480 minutes postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 23, 2015
Primary Completion (ACTUAL)
October 6, 2015
Study Completion (ACTUAL)
October 6, 2015
Study Registration Dates
First Submitted
September 27, 2019
First Submitted That Met QC Criteria
September 27, 2019
First Posted (ACTUAL)
October 1, 2019
Study Record Updates
Last Update Posted (ACTUAL)
October 1, 2019
Last Update Submitted That Met QC Criteria
September 27, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
Other Study ID Numbers
- CNS7056-014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abuse, Drug
-
Lund UniversityCompletedIntravenous Drug Abuse, S Aureus Colonization
-
Duke UniversityCompletedHealth Behavior | Opioid Use, Unspecified | Benzodiazepine Abuse | Prescription Drug Abuse (Not Dependent) | Benzodiazepine Dependent | Prescription Drug Abuse and DependencyUnited States
-
Stuart WillickSports Medicine Research and Testing Laboratory; Partnership for Clean CompetitionCompletedSports Drug Abuse | Abuse of Steroids or HormonesUnited States
-
Eli Lilly and CompanyCompletedPrescription Drug Abuse (Not Dependent) | Recreational Drug UseUnited States
-
Boston UniversityNational Institute on Drug Abuse (NIDA)WithdrawnIntravenous Drug Abuse
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)United States
-
National Institute on Drug Abuse (NIDA)Completed
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)Completed
-
INSYS Therapeutics IncCompletedDrug Abuse, MedicationCanada
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)
Clinical Trials on Remimazolam
-
Konkuk University Medical CenterNot yet recruiting
-
Nantes University HospitalPaion UK Ltd.CompletedStroke | COVID-19 | Sepsis | Shock | Trauma | Acute Respiratory FailureFrance
-
Acacia Pharma LtdPaion UK Ltd.Active, not recruitingPediatric ALLUnited States, Denmark
-
Paion UK Ltd.PRA Health SciencesCompleted
-
Tongji HospitalRecruitingBidirectional EndoscopyChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.CompletedSedation in the Upper Gastrointestinal EndoscopyChina
-
Tongji HospitalRecruitingEffect of DrugChina
-
Kangbuk Samsung HospitalNot yet recruitingHypotension on Induction